Jennewein Biotechnology announces another milestone in the worldwide approval of a new product generation, the “HMO-Mix.” The data of the toxicological study, with the title “A Safety Evaluation of Mixed Human Milk Oligosaccharides in Rats,” […]
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces the opening of a clinical study to evaluate the safety and preliminary clinical efficacy of MRx0518 in combination with […]
On January 2nd, the Psomagen–Macrogen Consortium announced the acquisition of all key assets of US company uBiome. Through the move, Psomagen has become a key player in the microbiome sector, a promising next-generation bio healthcare […]
Carbiotix (publ) (“Carbiotix”) announces today that the company has signed a collaboration agreement with the Department of Medicine at the University of Verona, Italy, to carry out a research study during H1 2020 in the […]
This month’s roundup begins with a paper describing what happens when bifidobacteria in the infant gut degrade human milk oligosaccharides; and another about the role of the infant airway microbiota in predicting later-life asthma. Next […]
Prescient Metabiomics, a subsidiary of Prescient Medicine Holdings, Inc., and CoreBiome, a wholly owned subsidiary of OraSure Technologies, Inc., announced today a collaboration to develop a new test called LifeKit® Prevent, which may represent a microbiome-driven […]
The microbial community populating the human body plays an important role in health and disease, but with few exceptions, how individual microbial species affect health and disease states remains poorly understood. A new study by […]
RB and Evolve BioSystems announce a partnership in the sale of Evivo®, Evolve BioSystems’ infant probiotic. The partnership leverages assets and expertise from both companies to drive scale in messaging directly to consumers and health […]
We have a mutualistic but complicated relationship with the collection of microbes in our gut known as the intestinal microbiome. This complex community of bacteria breaks down different food components, and releases nutrients such as […]
Da Volterra, a clinical-stage biopharmaceutical company developing innovative products to protect the intestinal microbiota, announced the results of DAV132- CL-1005, a Phase 1 clinical study which investigated the potential effect of DAV132 on the bioavailability […]
Caelus Health, which develops food supplements and pharmaceutical products for the prevention, early treatment and management of cardio-metabolic diseases, is entering into a strategic collaboration with Nestlé Health Science (NHSc). The aim is to further […]